COMPUMED TO PRESENT DATA COMPARING DIGITAL VS. FILM-BASED OSTEOPOROSIS DIAGNOSTICS AT INTERNATIONAL CONFERENCE IN CHINA

LOS ANGELES, May 24 2005 -- CompuMed, Inc. (CMPD.OB) -- a medical informatics company serving the healthcare community with diagnostic software solutions -- will present data comparing digital and standard film-based versions of its OsteoGram(R) osteoporosis screening system at the 3rd International Conference on Bone and Mineral Research (May 23-27) in Xij-an, China. The conference is organized under the auspices of the International Osteoporosis Foundation, and is one of the world's largest gatherings of researchers focused on improving osteoporosis diagnostics, treatment and prevention.

CompuMed President Jerry McLaughlin and Vice President of Technology Xiaoli Bi will present the data on Wednesday, May 25th in a study titled, "A CAD Bone Mineral Density Assessment Application for DICOM Compliant Platforms."

"We are honored to be invited to present OsteoGram data at one of the world's premiere osteoporosis conferences," said McLaughlin. "We are especially pleased to discuss our new diagnostic advancements in China, which is home to many of the estimated 200 million people worldwide suffering from osteoporosis."

The study compares diagnostic results achieved with CompuMed's DICOM (Digital Communications and Imaging in Medicine) compliant OsteoGram system against those achieved with the company's standard film-based system. The DICOM results were found to correlate highly with the film-based version, which has been used successfully for nearly 10 years to test osteoporosis on more than 130,000 patients worldwide. Over that time, the film-based OsteoGram has developed a reputation as an accurate, low-cost alternative to more cumbersome DXA equipment. The DICOM OsteoGram is built upon the computer protocol used for digital imaging equipment, including filmless x-ray machines. , which require dedicated and expensive equipment, computers, office space and staff.

"The results of the study suggest that the far more efficient DICOM OsteoGram performs BMD [Bone Mass Density] assessment without sacrificing quality or reliability," added McLaughlin. "The expanding Chinese market for digital x-ray equipment provides many excellent opportunities to bundle CompuMed's software-based system with rapidly proliferating DICIOM imaging platforms."

CompuMed introduced the DICOM-based OsteoGram to the Chinese market in April 2004 at the annual ChinaMed International Medical Instruments and Equipment Exhibition in Beijing. The system was jointly displayed with a CR (Computed Radiography) platform by Orex (Yokneam, Israel) -- a global leader in filmless medical imaging equipment.

The DICOM OsteoGram represents the latest advancement to CompuMed's popular software-based imaging system for screening, diagnosing and monitoring osteoporosis. It uses a digital image derived from filmless x-ray equipment to enable clinicians to perform accurate osteoporosis testing.

About CompuMed:

Founded in 1973, CompuMed, Inc. (BB:CMPD) is a leading provider of computer-aided telemedicine and diagnostics technology. The company's core products are the OsteoGram and CardioGram systems. The OsteoGram, which is cleared by the FDA for commercial use, is an accurate and precise technology for low-cost osteoporosis testing. The CardioGram system remotely interprets electrocardiograms and is used by private practice, government and corporate healthcare providers nationwide. CompuMed is headquartered in Los Angeles. Visit CompuMed at www.compumed.net or call (310) 258-5000.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks defined in this document. All such forward-looking statements are expressly qualified by these cautionary statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

CONTACT: Erik Deutsch - Tellem Worldwide, +1 (310) 479-6111 x.15, edeutsch@tellem.com